Literature DB >> 32087337

N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial.

Sudie E Back1, Kevin Gray2, Elizabeth Santa Ana3, Jennifer L Jones4, Amber M Jarnecke5, Jane E Joseph6, James Prisciandaro7, Therese Killeen8, Delisa G Brown9, Linda Taimina10, Ebele Compean11, Robert Malcolm12, Julianne C Flanagan13, Peter W Kalivas14.   

Abstract

Alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD) are two prevalent psychiatric conditions in the U.S. The co-occurrence of AUD and PTSD is also common, and associated with a more severe clinical presentation and worse treatment outcomes across the biopsychosocial spectrum (e.g., social and vocational functioning, physical health) as compared to either disorder alone. Despite the high co-occurrence and negative outcomes, research on effective medications for AUD/PTSD is sparse and there is little empirical evidence to guide treatment decisions. The study described in this paper addresses this knowledge gap by testing the efficacy of N-acetylcysteine (NAC) in reducing alcohol use and PTSD symptoms. Animal studies and prior clinical research suggest a role for NAC in the treatment of substance use disorders and PTSD via glutamate modulation. NAC is a cysteine pro-drug that stimulates the cystine-glutamate exchanger, normalizes glial glutamate transporters, and restores glutamatergic tone on presynaptic receptors in reward regions of the brain. Moreover, NAC is available over-the-counter, has a long-established safety record, and does not require titration to achieve the target dose. This paper describes the rationale, study design, and methodology of a 12-week, randomized, double-blind, placebo-controlled trial of NAC (2400 mg/day) among adults with co-occurring AUD and PTSD. Functional magnetic resonance imaging (fMRI) and proton magnetic resonance spectroscopy (1H-MRS) are utilized to investigate the neural circuitry and neurochemistry underlying comorbid AUD/PTSD and identify predictors of treatment outcome. This study is designed to determine the efficacy of NAC in the treatment of co-occurring AUD/PTSD and provide new information regarding mechanisms of action implicated in co-occurring AUD/PTSD.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Alcohol; Alcohol use disorder; N-acetylcysteine; PTSD; Posttraumatic stress disorder

Mesh:

Substances:

Year:  2020        PMID: 32087337      PMCID: PMC7333883          DOI: 10.1016/j.cct.2020.105961

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  65 in total

Review 1.  Overview of glutamatergic neurotransmission in the nervous system.

Authors:  Mark J Niciu; Benjamin Kelmendi; Gerard Sanacora
Journal:  Pharmacol Biochem Behav       Date:  2011-08-26       Impact factor: 3.533

2.  Psychophysiological and modulatory interactions in neuroimaging.

Authors:  K J Friston; C Buechel; G R Fink; J Morris; E Rolls; R J Dolan
Journal:  Neuroimage       Date:  1997-10       Impact factor: 6.556

3.  A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.

Authors:  Kevin M Gray; Susan C Sonne; Erin A McClure; Udi E Ghitza; Abigail G Matthews; Aimee L McRae-Clark; Kathleen M Carroll; Jennifer S Potter; Katharina Wiest; Larissa J Mooney; Albert Hasson; Sharon L Walsh; Michelle R Lofwall; Shanna Babalonis; Robert W Lindblad; Steven Sparenborg; Aimee Wahle; Jacqueline S King; Nathaniel L Baker; Rachel L Tomko; Louise F Haynes; Ryan G Vandrey; Frances R Levin
Journal:  Drug Alcohol Depend       Date:  2017-06-10       Impact factor: 4.492

4.  Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans.

Authors:  Shelley L Amen; Linda B Piacentine; Muhammad E Ahmad; Shi-Jiang Li; John R Mantsch; Robert C Risinger; David A Baker
Journal:  Neuropsychopharmacology       Date:  2010-12-15       Impact factor: 7.853

5.  Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985)

Authors:  M J Smilkstein; G L Knapp; K W Kulig; B H Rumack
Journal:  N Engl J Med       Date:  1988-12-15       Impact factor: 91.245

6.  Cocaine dependence with and without post-traumatic stress disorder: a comparison of substance use, trauma history and psychiatric comorbidity.

Authors:  S Back; B S Dansky; S F Coffey; M E Saladin; S Sonne; K T Brady
Journal:  Am J Addict       Date:  2000

7.  Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II.

Authors:  J B Saunders; O G Aasland; T F Babor; J R de la Fuente; M Grant
Journal:  Addiction       Date:  1993-06       Impact factor: 6.526

8.  The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.

Authors:  Michael Berk; Olivia M Dean; Sue M Cotton; Susan Jeavons; Michelle Tanious; Kristy Kohlmann; Karen Hewitt; Kirsteen Moss; Christine Allwang; Ian Schapkaitz; Jenny Robbins; Heidi Cobb; Felicity Ng; Seetal Dodd; Ashley I Bush; Gin S Malhi
Journal:  J Clin Psychiatry       Date:  2014-06       Impact factor: 4.384

9.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra.

Authors:  S W Provencher
Journal:  Magn Reson Med       Date:  1993-12       Impact factor: 4.668

10.  Cortico-amygdala coupling as a marker of early relapse risk in cocaine-addicted individuals.

Authors:  Meredith J McHugh; Catherine H Demers; Betty Jo Salmeron; Michael D Devous; Elliot A Stein; Bryon Adinoff
Journal:  Front Psychiatry       Date:  2014-02-27       Impact factor: 4.157

View more
  7 in total

1.  Clinical translational neuroimaging of the antioxidant effect of N-acetylcysteine on neural microstructure.

Authors:  Sue Y Yi; Brian R Barnett; McKenzie J Poetzel; Nicholas A Stowe; John-Paul J Yu
Journal:  Magn Reson Med       Date:  2021-09-30       Impact factor: 4.668

Review 2.  Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities.

Authors:  Mark D Namba; Jonna M Leyrer-Jackson; Erin K Nagy; M Foster Olive; Janet L Neisewander
Journal:  Front Neurosci       Date:  2021-04-15       Impact factor: 4.677

Review 3.  Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.

Authors:  Elizabeth M Burnette; Steven J Nieto; Erica N Grodin; Lindsay R Meredith; Brian Hurley; Karen Miotto; Artha J Gillis; Lara A Ray
Journal:  Drugs       Date:  2022-02-08       Impact factor: 9.546

Review 4.  The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders.

Authors:  Richard C J Bradlow; Michael Berk; Peter W Kalivas; Sudie E Back; Richard A Kanaan
Journal:  CNS Drugs       Date:  2022-03-22       Impact factor: 6.497

5.  The Impact of COVID-19 on Psychotherapy Participation Among Individuals With Posttraumatic Stress Disorder Enrolled in Treatment Research.

Authors:  Carmen P McLean; Sudie E Back; Christy Capone; Leslie Morland; Sonya B Norman; Sheila A M Rauch; Paula P Schnurr; Ellen Teng; Ron Acierno
Journal:  J Trauma Stress       Date:  2021-07-22

Review 6.  Astrocytes in cocaine addiction and beyond.

Authors:  Junshi Wang; Leanne M Holt; Hugh H Huang; Susan R Sesack; Eric J Nestler; Yan Dong
Journal:  Mol Psychiatry       Date:  2021-04-09       Impact factor: 15.992

Review 7.  N-acetylcysteine in substance use disorder: a lesson from preclinical and clinical research.

Authors:  Irena Smaga; Małgorzata Frankowska; Małgorzata Filip
Journal:  Pharmacol Rep       Date:  2021-06-06       Impact factor: 3.024

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.